Rheumatoid Arthritis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：1,166頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Rheumatoid Arthritis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2014’, provides an overview of the Rheumatoid Arthritis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2014’, provides an overview of the Rheumatoid Arthritis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 12
Rheumatoid Arthritis Overview 13
Therapeutics Development 14
Rheumatoid Arthritis - Therapeutics under Development by Companies 16
Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36
Rheumatoid Arthritis - Pipeline Products Glance 40
Rheumatoid Arthritis - Products under Development by Companies 44
Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 71
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 74
Rheumatoid Arthritis - Therapeutics Assessment 315
Drug Profiles 346
Rheumatoid Arthritis - Recent Pipeline Updates 924
Rheumatoid Arthritis - Dormant Projects 1076
Rheumatoid Arthritis - Discontinued Products 1099
Rheumatoid Arthritis - Product Development Milestones 1108
Appendix 1116
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2014 63
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2014 64
Number of Products under Development by Companies, H1 2014 66
Number of Products under Development by Companies, H1 2014 (Contd..1) 67
Number of Products under Development by Companies, H1 2014 (Contd..2) 68
Number of Products under Development by Companies, H1 2014 (Contd..3) 69
Number of Products under Development by Companies, H1 2014 (Contd..4) 70
Number of Products under Development by Companies, H1 2014 (Contd..5) 71
Number of Products under Development by Companies, H1 2014 (Contd..6) 72
Number of Products under Development by Companies, H1 2014 (Contd..7) 73
Number of Products under Development by Companies, H1 2014 (Contd..8) 74
Number of Products under Development by Companies, H1 2014 (Contd..9) 75
Number of Products under Development by Companies, H1 2014 (Contd..10) 76
Number of Products under Development by Companies, H1 2014 (Contd..11) 77
Number of Products under Development by Companies, H1 2014 (Contd..12) 78
Number of Products under Development by Companies, H1 2014 (Contd..13) 79
Number of Products under Development by Companies, H1 2014 (Contd..14) 80
Number of Products under Development by Companies, H1 2014 (Contd..15) 81
Number of Products under Development by Companies, H1 2014 (Contd..16) 82
Number of Products under Development by Companies, H1 2014 (Contd..17) 83
Number of Products under Development by Companies, H1 2014 (Contd..18) 84
Number of Products under Investigation by Universities/Institutes, H1 2014 86
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 87
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 88
Comparative Analysis by Late Stage Development, H1 2014 89
Comparative Analysis by Clinical Stage Development, H1 2014 90
Comparative Analysis by Early Stage Development, H1 2014 91
Comparative Analysis by Unknown Stage Development, H1 2014 92
Products under Development by Companies, H1 2014 93
Products under Development by Companies, H1 2014 (Contd..1) 94
Products under Development by Companies, H1 2014 (Contd..2) 95
Products under Development by Companies, H1 2014 (Contd..3) 96
Products under Development by Companies, H1 2014 (Contd..4) 97
Products under Development by Companies, H1 2014 (Contd..5) 98
Products under Development by Companies, H1 2014 (Contd..6) 99
Products under Development by Companies, H1 2014 (Contd..7) 100
Products under Development by Companies, H1 2014 (Contd..8) 101
Products under Development by Companies, H1 2014 (Contd..9) 102
Products under Development by Companies, H1 2014 (Contd..10) 103
Products under Development by Companies, H1 2014 (Contd..11) 104
Products under Development by Companies, H1 2014 (Contd..12) 105
Products under Development by Companies, H1 2014 (Contd..13) 106
Products under Development by Companies, H1 2014 (Contd..14) 107
Products under Development by Companies, H1 2014 (Contd..15) 108
Products under Development by Companies, H1 2014 (Contd..16) 109
Products under Development by Companies, H1 2014 (Contd..17) 110
Products under Development by Companies, H1 2014 (Contd..18) 111
Products under Development by Companies, H1 2014 (Contd..19) 112
Products under Development by Companies, H1 2014 (Contd..20) 113
Products under Development by Companies, H1 2014 (Contd..21) 114
Products under Development by Companies, H1 2014 (Contd..22) 115
Products under Development by Companies, H1 2014 (Contd..23) 116
Products under Development by Companies, H1 2014 (Contd..24) 117
Products under Development by Companies, H1 2014 (Contd..25) 118
Products under Development by Companies, H1 2014 (Contd..26) 119
Products under Investigation by Universities/Institutes, H1 2014 120
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 121
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 122
Rheumatoid Arthritis - Pipeline by Alcon, Inc., H1 2014 123
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2014 124
Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H1 2014 125
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H1 2014 126
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 127
Rheumatoid Arthritis - Pipeline by Amgen Inc., H1 2014 128
Rheumatoid Arthritis - Pipeline by AstraZeneca PLC, H1 2014 129
Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H1 2014 130
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline plc, H1 2014 131
Rheumatoid Arthritis - Pipeline by Genentech, Inc., H1 2014 132
Rheumatoid Arthritis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 133
Rheumatoid Arthritis - Pipeline by MedImmune, LLC, H1 2014 134
Rheumatoid Arthritis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 135
Rheumatoid Arthritis - Pipeline by Gilead Sciences, Inc., H1 2014 136
Rheumatoid Arthritis - Pipeline by Biotest AG, H1 2014 137
Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 138
Rheumatoid Arthritis - Pipeline by Merck & Co., Inc., H1 2014 139
Rheumatoid Arthritis - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 140
Rheumatoid Arthritis - Pipeline by Ablynx NV, H1 2014 141
Rheumatoid Arthritis - Pipeline by AbGenomics International, Inc., H1 2014 142
Rheumatoid Arthritis - Pipeline by Emergent BioSolutions Inc., H1 2014 143
Rheumatoid Arthritis - Pipeline by Novo Nordisk A/S, H1 2014 144
Rheumatoid Arthritis - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 145
Rheumatoid Arthritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 146
Rheumatoid Arthritis - Pipeline by Plexxikon Inc., H1 2014 147
Rheumatoid Arthritis - Pipeline by ViaCord, LLC, H1 2014 148
Rheumatoid Arthritis - Pipeline by arGentis Pharmaceuticals, LLC, H1 2014 149
Rheumatoid Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 150
Rheumatoid Arthritis - Pipeline by MediGene AG, H1 2014 151
Rheumatoid Arthritis - Pipeline by Celltrion, Inc., H1 2014 152
Rheumatoid Arthritis - Pipeline by TiGenix NV, H1 2014 153
Rheumatoid Arthritis - Pipeline by Pacira Pharmaceuticals, Inc., H1 2014 154
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corporation, H1 2014 155
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc., H1 2014 156
Rheumatoid Arthritis - Pipeline by Biocon Limited, H1 2014 157
Rheumatoid Arthritis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 158
Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 159
Rheumatoid Arthritis - Pipeline by Richter Gedeon Nyrt., H1 2014 160
Rheumatoid Arthritis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 161
Rheumatoid Arthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 162
Rheumatoid Arthritis - Pipeline by Pfizer Inc., H1 2014 163
Rheumatoid Arthritis - Pipeline by Ranbaxy Laboratories Limited, H1 2014 164
Rheumatoid Arthritis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 165
Rheumatoid Arthritis - Pipeline by Salix Pharmaceuticals Ltd., H1 2014 166
Rheumatoid Arthritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 167
Rheumatoid Arthritis - Pipeline by Toyama Chemical Co., Ltd., H1 2014 168
Rheumatoid Arthritis - Pipeline by UCB S.A., H1 2014 169
Rheumatoid Arthritis - Pipeline by Vertex Pharmaceuticals Incorporated., H1 2014 170
Rheumatoid Arthritis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 171
Rheumatoid Arthritis - Pipeline by Cell Therapeutics, Inc., H1 2014 172
Rheumatoid Arthritis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 173
Rheumatoid Arthritis - Pipeline by Sandoz Inc., H1 2014 174
Rheumatoid Arthritis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 175
Rheumatoid Arthritis - Pipeline by CEL-SCI Corporation, H1 2014 176
Rheumatoid Arthritis - Pipeline by Celgene Corporation, H1 2014 177
Rheumatoid Arthritis - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 178
Rheumatoid Arthritis - Pipeline by Incyte Corporation, H1 2014 179
Rheumatoid Arthritis - Pipeline by OPKO Health, Inc., H1 2014 180
Rheumatoid Arthritis - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 181
Rheumatoid Arthritis - Pipeline by Bone Medical Limited, H1 2014 182
Rheumatoid Arthritis - Pipeline by 4SC AG, H1 2014 183
Rheumatoid Arthritis - Pipeline by Addex Therapeutics, H1 2014 184
Rheumatoid Arthritis - Pipeline by EntreMed, Inc., H1 2014 185
Rheumatoid Arthritis - Pipeline by Harbor Therapeutics, Inc., H1 2014 186
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 187
Rheumatoid Arthritis - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 188
Rheumatoid Arthritis - Pipeline by Karo Bio AB, H1 2014 189
Rheumatoid Arthritis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 190
Rheumatoid Arthritis - Pipeline by Almirall, S.A., H1 2014 191
Rheumatoid Arthritis - Pipeline by Lupin Limited, H1 2014 192
Rheumatoid Arthritis - Pipeline by Mesoblast Limited, H1 2014 193
Rheumatoid Arthritis - Pipeline by Bionomics Limited, H1 2014 194
Rheumatoid Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2014 195
Rheumatoid Arthritis - Pipeline by Nutra Pharma Corporation, H1 2014 196
Rheumatoid Arthritis - Pipeline by Nuvo Research Inc., H1 2014 197
Rheumatoid Arthritis - Pipeline by Compugen Ltd., H1 2014 198
Rheumatoid Arthritis - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 199
Rheumatoid Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 200
Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 201
Rheumatoid Arthritis - Pipeline by Yuhan Corporation, H1 2014 202
Rheumatoid Arthritis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 203
Rheumatoid Arthritis - Pipeline by Pharmacyclics, Inc., H1 2014 204
Rheumatoid Arthritis - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 205
Rheumatoid Arthritis - Pipeline by Tolerx, Inc., H1 2014 206
Rheumatoid Arthritis - Pipeline by Handok Inc., H1 2014 207
Rheumatoid Arthritis - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2014 208
Rheumatoid Arthritis - Pipeline by Green Cross Corporation, H1 2014 209
Rheumatoid Arthritis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 210
Rheumatoid Arthritis - Pipeline by Nichi-Iko Pharmaceutical Co., Ltd., H1 2014 211
Rheumatoid Arthritis - Pipeline by LG Life Sciences, Ltd., H1 2014 212
Rheumatoid Arthritis - Pipeline by Biotie Therapies Corp., H1 2014 213
Rheumatoid Arthritis - Pipeline by Galapagos NV, H1 2014 214
Rheumatoid Arthritis - Pipeline by Synta Pharmaceuticals Corp., H1 2014 215
Rheumatoid Arthritis - Pipeline by Panacea Biotec Limited, H1 2014 216
Rheumatoid Arthritis - Pipeline by CrystalGenomics, Inc., H1 2014 217
Rheumatoid Arthritis - Pipeline by Sareum Holdings plc, H1 2014 218
Rheumatoid Arthritis - Pipeline by Protalex, Inc., H1 2014 219
Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H1 2014 220
Rheumatoid Arthritis - Pipeline by DiaMedica Inc., H1 2014 221
Rheumatoid Arthritis - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2014 222
Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd., H1 2014 223
Rheumatoid Arthritis - Pipeline by Morphotek, Inc., H1 2014 224
Rheumatoid Arthritis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 225
Rheumatoid Arthritis - Pipeline by Chroma Therapeutics Ltd., H1 2014 226
Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd., H1 2014 227
Rheumatoid Arthritis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2014 228
Rheumatoid Arthritis - Pipeline by Scynexis, Inc., H1 2014 229
Rheumatoid Arthritis - Pipeline by Affimed Therapeutics AG, H1 2014 230
Rheumatoid Arthritis - Pipeline by Axxam SpA, H1 2014 231
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H1 2014 232
Rheumatoid Arthritis - Pipeline by CIMAB S.A., H1 2014 233
Rheumatoid Arthritis - Pipeline by AcurePharma AB, H1 2014 234
Rheumatoid Arthritis - Pipeline by Ambit Biosciences Corporation, H1 2014 235
Rheumatoid Arthritis - Pipeline by Immupharma Plc, H1 2014 236
Rheumatoid Arthritis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 237
Rheumatoid Arthritis - Pipeline by Palau Pharma, S.A., H1 2014 238
List of Figures
Number of Products under Development for Rheumatoid Arthritis, H1 2014 63
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2014 64
Number of Products under Development by Companies, H1 2014 65
Number of Products under Investigation by Universities/Institutes, H1 2014 85
Comparative Analysis by Late Stage Development, H1 2014 89
Comparative Analysis by Clinical Stage Development, H1 2014 90
Comparative Analysis by Early Stage Products, H1 2014 91
Assessment by Monotherapy Products, H1 2014 364
Assessment by Combination Products, H1 2014 365
Number of Products by Top 10 Target, H1 2014 366
Number of Products by Stage and Top 10 Target, H1 2014 367
Number of Products by Top 10 Mechanism of Action, H1 2014 377
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 378
Number of Products by Top 10 Route of Administration, H1 2014 389
Number of Products by Stage and Top 10 Route of Administration, H1 2014 390
Number of Products by Top 10 Molecule Type, H1 2014 392
Number of Products by Stage and Top 10 Molecule Type, H1 2014 393
Table of Contents 2
Introduction 12
Rheumatoid Arthritis Overview 13
Therapeutics Development 14
Rheumatoid Arthritis - Therapeutics under Development by Companies 16
Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36
Rheumatoid Arthritis - Pipeline Products Glance 40
Rheumatoid Arthritis - Products under Development by Companies 44
Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 71
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 74
Rheumatoid Arthritis - Therapeutics Assessment 315
Drug Profiles 346
Rheumatoid Arthritis - Recent Pipeline Updates 924
Rheumatoid Arthritis - Dormant Projects 1076
Rheumatoid Arthritis - Discontinued Products 1099
Rheumatoid Arthritis - Product Development Milestones 1108
Appendix 1116
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2014 63
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2014 64
Number of Products under Development by Companies, H1 2014 66
Number of Products under Development by Companies, H1 2014 (Contd..1) 67
Number of Products under Development by Companies, H1 2014 (Contd..2) 68
Number of Products under Development by Companies, H1 2014 (Contd..3) 69
Number of Products under Development by Companies, H1 2014 (Contd..4) 70
Number of Products under Development by Companies, H1 2014 (Contd..5) 71
Number of Products under Development by Companies, H1 2014 (Contd..6) 72
Number of Products under Development by Companies, H1 2014 (Contd..7) 73
Number of Products under Development by Companies, H1 2014 (Contd..8) 74
Number of Products under Development by Companies, H1 2014 (Contd..9) 75
Number of Products under Development by Companies, H1 2014 (Contd..10) 76
Number of Products under Development by Companies, H1 2014 (Contd..11) 77
Number of Products under Development by Companies, H1 2014 (Contd..12) 78
Number of Products under Development by Companies, H1 2014 (Contd..13) 79
Number of Products under Development by Companies, H1 2014 (Contd..14) 80
Number of Products under Development by Companies, H1 2014 (Contd..15) 81
Number of Products under Development by Companies, H1 2014 (Contd..16) 82
Number of Products under Development by Companies, H1 2014 (Contd..17) 83
Number of Products under Development by Companies, H1 2014 (Contd..18) 84
Number of Products under Investigation by Universities/Institutes, H1 2014 86
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 87
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 88
Comparative Analysis by Late Stage Development, H1 2014 89
Comparative Analysis by Clinical Stage Development, H1 2014 90
Comparative Analysis by Early Stage Development, H1 2014 91
Comparative Analysis by Unknown Stage Development, H1 2014 92
Products under Development by Companies, H1 2014 93
Products under Development by Companies, H1 2014 (Contd..1) 94
Products under Development by Companies, H1 2014 (Contd..2) 95
Products under Development by Companies, H1 2014 (Contd..3) 96
Products under Development by Companies, H1 2014 (Contd..4) 97
Products under Development by Companies, H1 2014 (Contd..5) 98
Products under Development by Companies, H1 2014 (Contd..6) 99
Products under Development by Companies, H1 2014 (Contd..7) 100
Products under Development by Companies, H1 2014 (Contd..8) 101
Products under Development by Companies, H1 2014 (Contd..9) 102
Products under Development by Companies, H1 2014 (Contd..10) 103
Products under Development by Companies, H1 2014 (Contd..11) 104
Products under Development by Companies, H1 2014 (Contd..12) 105
Products under Development by Companies, H1 2014 (Contd..13) 106
Products under Development by Companies, H1 2014 (Contd..14) 107
Products under Development by Companies, H1 2014 (Contd..15) 108
Products under Development by Companies, H1 2014 (Contd..16) 109
Products under Development by Companies, H1 2014 (Contd..17) 110
Products under Development by Companies, H1 2014 (Contd..18) 111
Products under Development by Companies, H1 2014 (Contd..19) 112
Products under Development by Companies, H1 2014 (Contd..20) 113
Products under Development by Companies, H1 2014 (Contd..21) 114
Products under Development by Companies, H1 2014 (Contd..22) 115
Products under Development by Companies, H1 2014 (Contd..23) 116
Products under Development by Companies, H1 2014 (Contd..24) 117
Products under Development by Companies, H1 2014 (Contd..25) 118
Products under Development by Companies, H1 2014 (Contd..26) 119
Products under Investigation by Universities/Institutes, H1 2014 120
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 121
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 122
Rheumatoid Arthritis - Pipeline by Alcon, Inc., H1 2014 123
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2014 124
Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H1 2014 125
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H1 2014 126
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 127
Rheumatoid Arthritis - Pipeline by Amgen Inc., H1 2014 128
Rheumatoid Arthritis - Pipeline by AstraZeneca PLC, H1 2014 129
Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H1 2014 130
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline plc, H1 2014 131
Rheumatoid Arthritis - Pipeline by Genentech, Inc., H1 2014 132
Rheumatoid Arthritis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 133
Rheumatoid Arthritis - Pipeline by MedImmune, LLC, H1 2014 134
Rheumatoid Arthritis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 135
Rheumatoid Arthritis - Pipeline by Gilead Sciences, Inc., H1 2014 136
Rheumatoid Arthritis - Pipeline by Biotest AG, H1 2014 137
Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 138
Rheumatoid Arthritis - Pipeline by Merck & Co., Inc., H1 2014 139
Rheumatoid Arthritis - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 140
Rheumatoid Arthritis - Pipeline by Ablynx NV, H1 2014 141
Rheumatoid Arthritis - Pipeline by AbGenomics International, Inc., H1 2014 142
Rheumatoid Arthritis - Pipeline by Emergent BioSolutions Inc., H1 2014 143
Rheumatoid Arthritis - Pipeline by Novo Nordisk A/S, H1 2014 144
Rheumatoid Arthritis - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 145
Rheumatoid Arthritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 146
Rheumatoid Arthritis - Pipeline by Plexxikon Inc., H1 2014 147
Rheumatoid Arthritis - Pipeline by ViaCord, LLC, H1 2014 148
Rheumatoid Arthritis - Pipeline by arGentis Pharmaceuticals, LLC, H1 2014 149
Rheumatoid Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 150
Rheumatoid Arthritis - Pipeline by MediGene AG, H1 2014 151
Rheumatoid Arthritis - Pipeline by Celltrion, Inc., H1 2014 152
Rheumatoid Arthritis - Pipeline by TiGenix NV, H1 2014 153
Rheumatoid Arthritis - Pipeline by Pacira Pharmaceuticals, Inc., H1 2014 154
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corporation, H1 2014 155
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc., H1 2014 156
Rheumatoid Arthritis - Pipeline by Biocon Limited, H1 2014 157
Rheumatoid Arthritis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 158
Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 159
Rheumatoid Arthritis - Pipeline by Richter Gedeon Nyrt., H1 2014 160
Rheumatoid Arthritis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 161
Rheumatoid Arthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 162
Rheumatoid Arthritis - Pipeline by Pfizer Inc., H1 2014 163
Rheumatoid Arthritis - Pipeline by Ranbaxy Laboratories Limited, H1 2014 164
Rheumatoid Arthritis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 165
Rheumatoid Arthritis - Pipeline by Salix Pharmaceuticals Ltd., H1 2014 166
Rheumatoid Arthritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 167
Rheumatoid Arthritis - Pipeline by Toyama Chemical Co., Ltd., H1 2014 168
Rheumatoid Arthritis - Pipeline by UCB S.A., H1 2014 169
Rheumatoid Arthritis - Pipeline by Vertex Pharmaceuticals Incorporated., H1 2014 170
Rheumatoid Arthritis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 171
Rheumatoid Arthritis - Pipeline by Cell Therapeutics, Inc., H1 2014 172
Rheumatoid Arthritis - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014 173
Rheumatoid Arthritis - Pipeline by Sandoz Inc., H1 2014 174
Rheumatoid Arthritis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 175
Rheumatoid Arthritis - Pipeline by CEL-SCI Corporation, H1 2014 176
Rheumatoid Arthritis - Pipeline by Celgene Corporation, H1 2014 177
Rheumatoid Arthritis - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 178
Rheumatoid Arthritis - Pipeline by Incyte Corporation, H1 2014 179
Rheumatoid Arthritis - Pipeline by OPKO Health, Inc., H1 2014 180
Rheumatoid Arthritis - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 181
Rheumatoid Arthritis - Pipeline by Bone Medical Limited, H1 2014 182
Rheumatoid Arthritis - Pipeline by 4SC AG, H1 2014 183
Rheumatoid Arthritis - Pipeline by Addex Therapeutics, H1 2014 184
Rheumatoid Arthritis - Pipeline by EntreMed, Inc., H1 2014 185
Rheumatoid Arthritis - Pipeline by Harbor Therapeutics, Inc., H1 2014 186
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 187
Rheumatoid Arthritis - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 188
Rheumatoid Arthritis - Pipeline by Karo Bio AB, H1 2014 189
Rheumatoid Arthritis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 190
Rheumatoid Arthritis - Pipeline by Almirall, S.A., H1 2014 191
Rheumatoid Arthritis - Pipeline by Lupin Limited, H1 2014 192
Rheumatoid Arthritis - Pipeline by Mesoblast Limited, H1 2014 193
Rheumatoid Arthritis - Pipeline by Bionomics Limited, H1 2014 194
Rheumatoid Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2014 195
Rheumatoid Arthritis - Pipeline by Nutra Pharma Corporation, H1 2014 196
Rheumatoid Arthritis - Pipeline by Nuvo Research Inc., H1 2014 197
Rheumatoid Arthritis - Pipeline by Compugen Ltd., H1 2014 198
Rheumatoid Arthritis - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 199
Rheumatoid Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 200
Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 201
Rheumatoid Arthritis - Pipeline by Yuhan Corporation, H1 2014 202
Rheumatoid Arthritis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 203
Rheumatoid Arthritis - Pipeline by Pharmacyclics, Inc., H1 2014 204
Rheumatoid Arthritis - Pipeline by Protalix BioTherapeutics, Inc., H1 2014 205
Rheumatoid Arthritis - Pipeline by Tolerx, Inc., H1 2014 206
Rheumatoid Arthritis - Pipeline by Handok Inc., H1 2014 207
Rheumatoid Arthritis - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2014 208
Rheumatoid Arthritis - Pipeline by Green Cross Corporation, H1 2014 209
Rheumatoid Arthritis - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 210
Rheumatoid Arthritis - Pipeline by Nichi-Iko Pharmaceutical Co., Ltd., H1 2014 211
Rheumatoid Arthritis - Pipeline by LG Life Sciences, Ltd., H1 2014 212
Rheumatoid Arthritis - Pipeline by Biotie Therapies Corp., H1 2014 213
Rheumatoid Arthritis - Pipeline by Galapagos NV, H1 2014 214
Rheumatoid Arthritis - Pipeline by Synta Pharmaceuticals Corp., H1 2014 215
Rheumatoid Arthritis - Pipeline by Panacea Biotec Limited, H1 2014 216
Rheumatoid Arthritis - Pipeline by CrystalGenomics, Inc., H1 2014 217
Rheumatoid Arthritis - Pipeline by Sareum Holdings plc, H1 2014 218
Rheumatoid Arthritis - Pipeline by Protalex, Inc., H1 2014 219
Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H1 2014 220
Rheumatoid Arthritis - Pipeline by DiaMedica Inc., H1 2014 221
Rheumatoid Arthritis - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2014 222
Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd., H1 2014 223
Rheumatoid Arthritis - Pipeline by Morphotek, Inc., H1 2014 224
Rheumatoid Arthritis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 225
Rheumatoid Arthritis - Pipeline by Chroma Therapeutics Ltd., H1 2014 226
Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd., H1 2014 227
Rheumatoid Arthritis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2014 228
Rheumatoid Arthritis - Pipeline by Scynexis, Inc., H1 2014 229
Rheumatoid Arthritis - Pipeline by Affimed Therapeutics AG, H1 2014 230
Rheumatoid Arthritis - Pipeline by Axxam SpA, H1 2014 231
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H1 2014 232
Rheumatoid Arthritis - Pipeline by CIMAB S.A., H1 2014 233
Rheumatoid Arthritis - Pipeline by AcurePharma AB, H1 2014 234
Rheumatoid Arthritis - Pipeline by Ambit Biosciences Corporation, H1 2014 235
Rheumatoid Arthritis - Pipeline by Immupharma Plc, H1 2014 236
Rheumatoid Arthritis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 237
Rheumatoid Arthritis - Pipeline by Palau Pharma, S.A., H1 2014 238
List of Figures
Number of Products under Development for Rheumatoid Arthritis, H1 2014 63
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H1 2014 64
Number of Products under Development by Companies, H1 2014 65
Number of Products under Investigation by Universities/Institutes, H1 2014 85
Comparative Analysis by Late Stage Development, H1 2014 89
Comparative Analysis by Clinical Stage Development, H1 2014 90
Comparative Analysis by Early Stage Products, H1 2014 91
Assessment by Monotherapy Products, H1 2014 364
Assessment by Combination Products, H1 2014 365
Number of Products by Top 10 Target, H1 2014 366
Number of Products by Stage and Top 10 Target, H1 2014 367
Number of Products by Top 10 Mechanism of Action, H1 2014 377
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 378
Number of Products by Top 10 Route of Administration, H1 2014 389
Number of Products by Stage and Top 10 Route of Administration, H1 2014 390
Number of Products by Top 10 Molecule Type, H1 2014 392
Number of Products by Stage and Top 10 Molecule Type, H1 2014 393
